News & Updates
Filter by Specialty:
Investigational imaging agent holds promise for diagnosing renal cancer
In the pivotal phase III ZIRCON study, PET/CT imaging with 89Zr-DFO-girentuximab, an investigational imaging agent, demonstrated potential in the noninvasive identification of clear-cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses (IDRM).
Investigational imaging agent holds promise for diagnosing renal cancer
17 Apr 2023Mirabegron may improve sexual function in adults with OAB
Mirabegron, a ß3 adrenoceptor agonist, delivers benefit for both men and women with overactive bladder (OAB) who are experiencing sexual dysfunction, a systematic review and meta-analysis reports.
Mirabegron may improve sexual function in adults with OAB
13 Apr 2023Watch-and-wait approach for rectal cancer may boost potential of maintaining good quality of life
Patients with rectal cancer who are monitored using a watch-and-wait approach are more likely to have a good quality of life, whereas those who undergo surgery appear to experience deterioration in quality of life and functional outcome, as reported in a study.
Watch-and-wait approach for rectal cancer may boost potential of maintaining good quality of life
03 Apr 2023Novel device delivers improvements for BPH symptoms
The Optilume™ BPH Catheter System, a novel minimally invasive surgical therapy (MIST), provided rapid improvements for men with benign prostatic hyperplasia (BPH), the PINNACLE trial reports.
Novel device delivers improvements for BPH symptoms
31 Mar 2023Dysmenorrhoea, urinary pain predict deep infiltrating endometriosis
Severe dysmenorrhoea, pain related to urinary and gastrointestinal tracts, higher fertility desire and infertility rate are all associated with deep infiltrating endometriosis, according to a Singapore study. On the other hand, heavy menstrual bleeding is predictive of adenomyosis.
Dysmenorrhoea, urinary pain predict deep infiltrating endometriosis
28 Mar 2023Use of monitoring tests remains low in prostate cancer
Low use of recommended monitoring tests, including repeat prostate biopsy, persists among patients with localized prostate cancer undergoing observation, a recent study has found.